Peter M. Chumakov
Impact in
- Oncology top 0.5%
- Cancer-related Molecular Pathways
- Biotechnology top 0.5%
- Cancer Research and Treatments
Papers in
-
- Cancer Research and Treatments 35
- Oncology 74
- Cancer-related Molecular Pathways 57
- CAR-T cell therapy research 14
- Co-authors
- Anna SablinaAndrei V. BudanovJ. E. KravchenkoLarissa S. AgapovaG. V. IlyinskayaKopnin BpElena FeinsteinEugene V. Koonin
- Journals
- Oncogene (7 papers)Cancers (5 papers)Nucleic Acids Research (4 papers)Oncotarget (4 papers)Molecular Therapy — Oncolytics (3 papers)
- Partner nations
- RussiaUnited StatesUnited Kingdom
In The Last Decade
Peter M. Chumakov
169 papers receiving 6.5k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Oncology 3.0k
- Biotechnology 822
- Cancer Research 1.3k
- Molecular Biology 4.6k
- Aging 97
Countries citing papers authored by Peter M. Chumakov
This map shows the geographic impact of Peter M. Chumakov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Chumakov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Chumakov more than expected).
Fields of papers citing papers by Peter M. Chumakov
This network shows the impact of papers produced by Peter M. Chumakov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Chumakov. The network helps show where Peter M. Chumakov may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter M. Chumakov, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 3 | |
| 4 | 2023 | 11 | |
| 5 | 2023 | 2 | |
| 6 | 2022 | 10 | |
| 7 | 2022 | 9 | |
| 8 | 2020 | 2 | |
| 9 | 2018 | 3 | |
| 10 | 2018 | 34 | |
| 11 | 2017 | 15 | |
| 12 | 2017 | 13 | |
| 13 | 2015 | 54 | |
| 14 | 2012 | 10 | |
| 15 | 2010 | 122 | |
| 16 | 2010 | 16 | |
| 17 | 2008 | 160 | |
| 18 | 2007 | 116 | |
| 19 | 1999 | 39 | |
| 20 | 1989 | 7 |
About Peter M. Chumakov
Peter M. Chumakov is a scholar working on Biotechnology, Oncology, Genetics, Molecular Biology and Aging, having authored 175 papers that have together received 6.7k indexed citations. Recurring topics across this work include Virus-based gene therapy research (72 papers), Cancer-related Molecular Pathways (57 papers), Cancer Research and Treatments (35 papers), Viral Infectious Diseases and Gene Expression in Insects (15 papers), RNA Interference and Gene Delivery (14 papers), Viral gastroenteritis research and epidemiology (14 papers), CAR-T cell therapy research (14 papers) and RNA modifications and cancer (14 papers). The work is most often cited by research in Oncology (3.0k citations), Biotechnology (822 citations), Cancer Research (1.3k citations), Molecular Biology (4.6k citations) and Aging (97 citations). Peter M. Chumakov has collaborated with scholars based in Russia, United States and United Kingdom. Frequent co-authors include Anna Sablina, Andrei V. Budanov, J. E. Kravchenko, Larissa S. Agapova, G. V. Ilyinskaya, Kopnin Bp, Elena Feinstein, Eugene V. Koonin, Elena N. Pugacheva and Andrei V. Gudkov. Their work appears in journals such as Oncogene, Cancers, Nucleic Acids Research, Oncotarget and Molecular Therapy — Oncolytics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.